PALYATİF BAKIM ÜNİTESİNE YATAN HASTALARIN BİYOKİMYASAL PARAMETRELERİNİN SAĞKALIMLA İLİŞKİSİ

Amaç: Bu çal›flmadaki amac›m›z palyatif bak›m servisine yatan hastalar›n biyokimyasal parametrelerinin sa¤kal›mla iliflkisini araflt›rmak ve benzer çal›flmalar ile karfl›laflt›rmakt›r. Yöntem: Malatya E¤itim ve Araflt›rma Hastanesi palyatif bak›m servisinde Alzheimer. kanser ve serebrovasküler hastal›¤› olup sa¤kal›m süresi 4 ay› aflmayan 237 hastan›n dosyas› incelendi. 115 hasta çal›flmaya dahil edildi. Yetersiz dosya bilgileri olan, taburculu¤u yap›lan, hemotolojik hastal›¤› veya multiorgan yetmezli¤i olan ve 48 saatten az yatan hastalar çal›flmaya dahil edilmedi. Hastalar›n yatt›klar›ndaki hastal›k türü, cinsiyet, yafl, üre, kreatinin, AST, ALT, Albumin, P, Na, K, CL, Crp, lökosit, lenfosit yüzdesi, trombosit da¤›l›m aral›¤›, ortalama trombosit hacmi, toplam sa¤kal›m günleri hasta kay›tlar›ndan elde edildi. Sa¤kal›m günleri 0-30 gün, 31-60 gün, 61-90 gün ve 91-120 gün olarak grupland›r›ld›. Bulgular: Ölçülen ALT ve Crp düzeylerinin sa¤kal›mla olan iliflkisi istatistiksel olarak anlaml› ç›km›flt›r. Hastalar›n lenfosit yüzdeleri istatistiksel olarak anlaml› ç›kmam›flt›r fakat p de¤erinin anlaml› k›sm›na çok yaklaflm›flt›r. Alzheimer, kanser ve SVO hastalar›n›n laboratuar bulgular› aras›nda yap›lan karfl›laflt›rmada AST, Na ve trombosit da¤›l›m aral›¤› de¤erleri anlaml› sonuç vermifltir. Sonuç: Hastal›¤›n semptomlar›n› ve uygulanan tedavilerin yan etkilerini önlemek veya azaltmak, yaflam kalitesini en yüksek düzeyde tutmak için palyatif bak›mda özellikle Na ve Crp de¤erlerine önem verilmesi gerekti¤ini düflünmekteyiz.

THE RELATIONSHIP BETWEEN SURVIVAL AND BIOCHEMICAL PARAMETERS OF PATIENTS ADMITTED TO PALLIATIVE CARE UNIT

PDF

___

Nakajima N, Hata Y, Kusumuto K. A clinicals tudy on the influence of hydration volume on the signs of terminally ill cancer patients with abdominal malignancies. J Palliat Med 2013; 16: 185-189.
Morrison RS, Meier DE. Clinical practice. Palliative care. N Engl J Med 2004; 350: 2582-2590.
Steinhauser KE, Christakis NA, Clipp EC, McNeilly M, McIntyre L, Tulsky JA. Factors considered important at the end of life by patients. family. physicians. and other care providers. JAMA 2000; 284: 2476-2482.
Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999; 340: 448-454.
Hogarth MB, Gallimore R, Savage P. et al. Acute phase proteins, C-reactive protein and serum amyloid A protein, as prognostic markers in the elderly inpatient. Age Ageing 1997; 26: 153-158.
Karaflahin Ö, Taflar PT, Timur Ö, et al. Palyatif bak›m alan geriyatrik hastalarda enfeksiyon tan› ve prognozunda laboratuvar belirteçlerin de¤eri. Tepecik E¤it. ve Araflt. Hast. Dergisi 2016; 26: 238-242.
Weinstein PS, Skinner M, Sipe JD, Lokich JJ, Zamcheck N, Cohen AS. Acute-phase proteins or tumour markers: the role of SAA, SAP, CRP and CEA as indicators of metastasis in a broad spectrum of neoplastic diseases. Scand J Immunol 1984; 19: 193-198.
Fujikawa K, Matsui Y, Oka H, Fukuzawa S, Takeuchi H. Serum C-reactive protein level and the impact of cytoreductive surgery in patients with metastatic renal cell carcinoma. J Urol 1999; 162: 1934-1937.
Ravel R. Clinical Laboratory Medicine: Clinical application of Laboratory Data St. Louis. Missouri. Mosby-Year Book, Ine. 1995; 314-316.
Rosner MH, Dalkin AC. Electrolyte disorders associated with cancer. Adv Chronic Kidney Dis 2014; 21: 7-17.
Ahluwalia V, Wade JB, Thacker L et al. Differential impact of hyponatremia and hepatic encephalopathy on health-related quality of life and brain metabolite abnormalities in cirrhosis. J Hepatol 2013; 59: 467-473.
Wannamethee SG. Shaper AG. Lennon L. Papacosta O. Whincup P. Mild hyponatremia, hypernatremia and incident cardiovascular disease and mortality in older men: a population-based cohort study. Nutr Metab Cardiovasc Dis 2016; 26: 12-9.
Gefen S. Joffe E. Mayan H. Justo D. Recurrent hospitalizations with moderate to severe hyponatremia in older adults and its associated mortality. Eur J Intern Med 2014; 25: 624-628.
Mohan S. Gu S. Parikh A. Radhakrishnan J. Prevalence of hyponatremia and association with mortality: Results from NHANES. Am J Med 2013; 126: 1127-1137.
Doshi SM. Shah P. Lei X. Lahoti A. Salahudeen AK. Hyponatremia in hospitalized patients and its impact on clinical outcomes. Am J Kidney Dis 2012; 59: 222-228.
Cohen MZ. Torres-Vigil I. Burbach BE. de la Rosa A. Bruera E. The meaning of parenteral hydration to family care givers and patients with advanced cancer receiving hospice care. J Pain Symptom Manage 2012; 43: 855-865.
Vieira J. Nunes G. Santos. CA. Fonseca J. Serum electrolytes and outcome in patients undergoing endoscopic gastrostomy. Arq Gastroenterol 2018; 55: 41-45.
Holland-Bill L, Christiansen CF. Heide-Jørgensen U, et al. Hyponatremia and mortality risk: a Danish cohort study of 279508 acutely hospitalized patients. Eur J Endocrinol 2015; 173: 71-81.
Sternal D, Wilczyiski K, Szewieczek J. Pressure ulcers in palliative ward patients: hyponatremia and low blood pressure as indicators of risk. Clin Interv Aging 2016; 12: 37-44.
fien F. Çiftçi R. Erdemli HK. Kocabafl R. K›l›ç L. Y›ld›z ‹. Onkoloji Hastalar›nda Hiponatremi S›kl›¤› ve Sa¤kal›mla ‹liflkisi. Türk Klinik Biyokimya Derg 2014; 12: 37-43.
Petereit C. Zaba O. Teber I. Grohé C. Is hyponatremia a prognostic marker of survival for lungcancer? Pneumologie 2011; 65: 565-571.
Rosner MH. Dalkin AC. Electrolyte disorders associated with cancer. Adv Chronic Kidney Dis 2014; 21: 7-17.
Upadhyay A. Jaber BL. Madias NE. Epidemiology of hyponatremia. Semin Nephrol 2009; 29: 227-238.
Akarsu S. Kurt ANÇ. Kurt A. Varol ‹. fien Y. De¤iflik hastal›k gruplar›nda trombosit hacim de¤iflkenleri. Türk Pediatri Arflivi 2006; 41: 208-213.